CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 31.91×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.02BCNY1.79B · vs all stocks (USD)
Revenue (TTM)
0.00CNYvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
50.17%vs all stocks
Market Capitalization
12.02BCNY1.79B · vs all stocks (USD)
Enterprise Value
10.71BCNY1.59B · vs all stocks (USD)
Forward P/E
-69.95xvs Biotechnology peers
Price to Book (MRQ)
7.36xvs Biotechnology peers
Enterprise to EBITDA
-56.43xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-8.97%vs Biotechnology peers
Return on Equity (TTM)
-9.23%vs Biotechnology peers
Revenue (TTM)
0.00CNYvs all stocks (USD)
Revenue per Share (TTM)
0.00CNYUpdated Aug 21, 2026Gross Profit (TTM)
0.00CNYvs all stocks (USD)
EBITDA (TTM)
-189.88MCNY-28.24M · vs all stocks (USD)
Net Income (TTM)
-170.50MCNY-25.36M · vs all stocks (USD)
Operating Cash Flow (TTM)
-127.53MCNY-18.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-154.02MCNY-22.90M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00CNYFY2025 · Dec 31, 2025Gross Profit
0.00CNYFY2025 · Dec 31, 2025Operating Income
-158.43MCNY-23.56M · vs all stocks (USD)
Pre-tax Income
-153.83MCNYFY2025 · Dec 31, 2025Income Tax Expense
189.56KCNYFY2025 · Dec 31, 2025Net Income
-154.02MCNYFY2025 · Dec 31, 2025EBIT
-153.73MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-142.76MCNYFY2025 · Dec 31, 2025Research & Development
120.96MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
379.83KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
95.13KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4000CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
385.04MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
385.04MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-154.02MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-162.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
-173.22MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.01BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-154.02MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.89MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
113.46KCNYFY2025 · Dec 31, 2025Capital Expenditures
-10.65MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.29BCNYFY2025 · Dec 31, 2025Sale of Investments
830.45MCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.61MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-468.01MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-17.34KCNYFY2025 · Dec 31, 2025Other Financing Charges
1.49BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.49BCNYFY2025 · Dec 31, 2025Shares Outstanding
450.04MSharesUpdated Aug 21, 2026Float Shares
178.58MSharesUpdated Aug 21, 2026% Held by Insiders
49.09%vs all stocks
% Held by Institutions
8.75%vs all stocks
Total Cash (MRQ)
1.52BCNY226.23M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.38CNYUpdated Aug 21, 2026Total Debt (MRQ)
3.83MCNY569.51K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0024xvs Biotechnology peers
Current Ratio (MRQ)
31.91xvs Biotechnology peers
Book Value per Share (MRQ)
3.62CNYUpdated Aug 21, 2026Total Assets
1.72BCNY255.26M · vs all stocks (USD)
Total Current Assets
1.64BCNYFY2025 · Dec 31, 2025Total Liabilities
47.56MCNYFY2025 · Dec 31, 2025Total Non-current Assets
79.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.01MCNYFY2025 · Dec 31, 2025Total Current Liabilities
45.55MCNYFY2025 · Dec 31, 2025Cash
1.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.01BCNYFY2025 · Dec 31, 2025Other Short-term Investments
572.44MCNYFY2025 · Dec 31, 2025Inventory
76.11KCNYFY2025 · Dec 31, 2025Accounts Payable
29.28MCNYFY2025 · Dec 31, 2025Short-term Debt
3.58MCNYFY2025 · Dec 31, 2025Long-term Debt
817.88KCNYFY2025 · Dec 31, 2025Common Stock (Book)
450.04MCNYFY2025 · Dec 31, 2025Retained Earnings
-588.03MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.67BCNY248.19M · vs all stocks (USD)
52-Week Low
17.78CNYUpdated Aug 21, 202652-Week High
57.47CNYUpdated Aug 21, 202652-Week Change
50.17%vs all stocks
50-Day MA
29.71CNYUpdated Aug 21, 2026200-Day MA
35.26CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.00MSharesUpdated Aug 21, 2026Avg 30-Day Volume
7.04MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.4200CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 31.91×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 31.91Industry median: 5.50Industry P95: 22.03Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.79B, above the global median of $1.15BNotable
Market cap (USD): 1,786,896,198.574Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heron Neutron Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Medlive Technology Co. Ltd.
4 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Hebei Sailhero Environmental Protection Hi-Tech Co., Ltd.
4 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Zhejiang Zhaolong Interconnect Co., Ltd.
4 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration